Buckley Wealth Management LLC Sells 222 Shares of Amgen Inc. (NASDAQ:AMGN)

Buckley Wealth Management LLC lessened its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 0.8% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 26,268 shares of the medical research company’s stock after selling 222 shares during the quarter. Amgen accounts for approximately 2.4% of Buckley Wealth Management LLC’s portfolio, making the stock its 14th largest position. Buckley Wealth Management LLC’s holdings in Amgen were worth $7,469,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the company. Vanguard Group Inc. grew its stake in shares of Amgen by 0.3% in the 3rd quarter. Vanguard Group Inc. now owns 49,035,981 shares of the medical research company’s stock worth $13,178,910,000 after acquiring an additional 165,636 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in shares of Amgen by 3.9% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 6,564,710 shares of the medical research company’s stock worth $1,890,769,000 after buying an additional 243,720 shares during the last quarter. Royal Bank of Canada boosted its holdings in shares of Amgen by 14.8% in the 4th quarter. Royal Bank of Canada now owns 5,831,624 shares of the medical research company’s stock worth $1,679,625,000 after buying an additional 751,947 shares during the last quarter. Norges Bank purchased a new position in shares of Amgen in the 4th quarter worth about $1,556,912,000. Finally, California Public Employees Retirement System boosted its holdings in shares of Amgen by 22.0% in the 4th quarter. California Public Employees Retirement System now owns 2,716,088 shares of the medical research company’s stock worth $782,288,000 after buying an additional 490,539 shares during the last quarter. Institutional investors own 76.50% of the company’s stock.

Insider Buying and Selling at Amgen

In other Amgen news, SVP Nancy A. Grygiel sold 2,117 shares of the firm’s stock in a transaction on Friday, May 3rd. The stock was sold at an average price of $313.09, for a total transaction of $662,811.53. Following the completion of the transaction, the senior vice president now owns 9,883 shares of the company’s stock, valued at $3,094,268.47. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.69% of the company’s stock.

Amgen Trading Down 0.3 %

AMGN stock traded down $0.96 on Friday, reaching $312.73. The company’s stock had a trading volume of 751,250 shares, compared to its average volume of 2,768,991. The business has a fifty day simple moving average of $299.67 and a two-hundred day simple moving average of $291.67. Amgen Inc. has a 12-month low of $218.44 and a 12-month high of $329.72. The firm has a market cap of $167.76 billion, a PE ratio of 44.81, a PEG ratio of 2.83 and a beta of 0.60. The company has a debt-to-equity ratio of 11.96, a quick ratio of 0.98 and a current ratio of 1.42.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Thursday, May 2nd. The medical research company reported $3.96 EPS for the quarter, topping analysts’ consensus estimates of $3.76 by $0.20. Amgen had a return on equity of 156.21% and a net margin of 12.74%. The company had revenue of $7.45 billion during the quarter, compared to analyst estimates of $7.45 billion. During the same quarter last year, the firm posted $3.98 earnings per share. The firm’s revenue was up 22.0% on a year-over-year basis. As a group, research analysts forecast that Amgen Inc. will post 19.47 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on AMGN shares. TD Cowen dropped their price objective on shares of Amgen from $370.00 to $360.00 and set a “buy” rating on the stock in a report on Wednesday, April 17th. Truist Financial reaffirmed a “buy” rating and set a $320.00 price objective on shares of Amgen in a report on Friday, April 12th. William Blair raised shares of Amgen from a “market perform” rating to an “outperform” rating in a report on Friday, May 3rd. BMO Capital Markets upped their price objective on shares of Amgen from $336.00 to $355.00 and gave the company an “outperform” rating in a report on Friday, May 3rd. Finally, Raymond James started coverage on shares of Amgen in a report on Thursday, March 28th. They set a “market perform” rating on the stock. Ten research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to MarketBeat.com, Amgen has an average rating of “Moderate Buy” and a consensus price target of $307.35.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.